Ibuprofen STADA 400 mg peroralni prašek Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ibuprofen stada 400 mg peroralni prašek

stada arzneimittel ag - ibuprofen - peroralni prašek - ibuprofen 400 mg / 1 vrečica - ibuprofen

Kvetiapin Lambda Therapeutic 200 mg tablete s podaljšanim sproščanjem Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kvetiapin lambda therapeutic 200 mg tablete s podaljšanim sproščanjem

lambda therapeutics limited - kvetiapin - tableta s podaljšanim sproščanjem - kvetiapin 200 mg / 1 tableta - kvetiapin

Kaspofungin STADA 70 mg prašek za koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kaspofungin stada 70 mg prašek za koncentrat za raztopino za infundiranje

stada arzneimittel ag - kaspofungin - prašek za koncentrat za raztopino za infundiranje - kaspofungin 70 mg / 1 viala - kaspofungin

Atorvastatin Stada Arzneimittel 40 mg filmsko obložene tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

atorvastatin stada arzneimittel 40 mg filmsko obložene tablete

stada arzneimittel ag - atorvastatin - filmsko obložena tableta - atorvastatin 40 mg / 1 tableta - atorvastatin

Razagilin STADA 1 mg tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

razagilin stada 1 mg tablete

stada arzneimittel ag - razagilin - tableta - razagilin 1 mg / 1 tableta - razagilin

Sildenafil Stada 20 mg filmsko obložene tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sildenafil stada 20 mg filmsko obložene tablete

stada arzneimittel ag - sildenafil - filmsko obložena tableta - sildenafil 20 mg / 1 tableta - sildenafil

Topotekan Accord 1 mg/ml koncentrat za raztopino za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

topotekan accord 1 mg/ml koncentrat za raztopino za infundiranje

accord healthcare - topotekan - koncentrat za raztopino za infundiranje - topotekan 1 mg / 1 ml - topotekan

Rivaroxaban Accord Evropska unija - slovenščina - EMA (European Medicines Agency)

rivaroxaban accord

accord healthcare s.l.u. - rivaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotična sredstva - preprečevanje venska trombembolija (vte) pri odraslih bolnikih, ki so v postopku izbirni kirurški zamenjavi kolka ali kolena. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 for haemodynamically unstable pe patients. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 za haemodynamically nestabilno pe bolnikov). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 in 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.